From OHC

May 29, 2024

Colorectal cancer is the third-leading cause of cancer deaths in men and the fourth-leading cause in women in the United States.  Treatment typically includes surgery, radiation, chemotherapy, and targeted therapies, with new developments in advanced treatments coming to market regularly.  OHC is proud to announce its participation in a vital clinical trial for a novel colorectal cancer vaccine, (RO7198457), offering this groundbreaking option to a select group of patients.

What is the Trial About?

OHC medical oncologist, hematologist, and principal investigator Mark E. Johns, MD, explains the details of this clinical trial.  “This revolutionary trial is designed to assess the safety and effectiveness of a new vaccine in preventing colorectal cancer from returning after successful treatment,” states Dr. Johns. The study specifically targets patients with stage two or three colorectal cancer who have undergone complete surgical removal of the tumor, as well as have the presence of circulating DNA prior to the start of chemotherapy.

Why is OHC Participating?

“OHC is dedicated to providing our patients with cutting-edge advancements in colorectal cancer care. By participating in this clinical trial, we offer our patients the unique opportunity to be at the forefront of cancer medicine,” explains Dr. Johns. This vaccine has the potential to significantly improve patient outcomes by offering a future free from the worry of recurrence after a challenging diagnosis.

The Importance of Clinical Trials

Clinical trials play a crucial role in driving medical progress and developing new treatments for various diseases, including colorectal cancer. Patients who participate in these trials not only gain access to potentially groundbreaking treatments but also make a significant contribution to scientific research.

Sharing Awareness and Patient Support

The trial is only available in the region at OHC.  “We are honored to be selected as one of the few sites offering this critical clinical trial,” said Dr. Johns.  “Colon cancer continues to pose a major public health challenge, and we are committed to exploring innovative approaches to improve patient outcomes. This vaccine holds immense promise, and we are eager to contribute to its evaluation.”

How to Get Involved

OHC is actively recruiting patients who may be eligible for this exciting clinical trial.  If you are interested in learning more about this specific trial or colorectal cancer treatment options at OHC, please contact us at 888-649-4800 or visit our website at

This clinical trial for a new colorectal cancer vaccine represents a significant step forward in the fight against this disease. OHC’s participation reflects our unwavering commitment to providing our patients with access to the latest advancements in cancer care and research.

Additional Resources

For more details about the clinical trial itself, you can visit at

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *